Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2/3 study of S-268019 for COVID-19 prevention
jRCT2031210383Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of S-268019-b in coronavirus disease 2019 (COVID-19), sponsored by Shionogi & Co., Ltd. Primary endpoints: Incidence of adverse events and related safety events and SARS-CoV-2 neutralizing antibody titer on Day 239. Started Oct 2021; status: completed.
02
Drugs
S-268019-b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210383.